Valuation: Beta Bionics, Inc.

Market Cap 635M 551M 516M 472M 891M 60.47B 902M 6.03B 2.37B 30.21B 2.38B 2.33B 101B P/E 2026 *
-6.59x
P/E 2027 * -6.55x
Enterprise Value 497M 432M 404M 370M 698M 47.39B 707M 4.73B 1.86B 23.68B 1.87B 1.83B 78.81B EV / Sales 2026 *
3.72x
EV / Sales 2027 * 3.08x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week-1.12%
Current month+9.98%
1 month-15.61%
3 months+33.49%
6 months+7.87%
Current year-53.69%
1 week 12.73
Extreme 12.73
14.68
1 month 12.73
Extreme 12.73
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
6/24/26 A Sell

Executive/Senior Manager

-1,258 0.0028%
2/27/26 A Sell

Executive/Senior Manager

59,813 0.1359%
2/27/26 A Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-1.12%-7.17% - 635M
+0.38%+0.56%+29.20%+5.72% 214B
+0.16%+1.94%+2.46%-21.50% 141B
-0.40%+5.88%-21.17%+20.82% 132B
+3.27%+7.17%-52.11%-2.80% 71.45B
+0.39%+2.76%+13.62%+12.28% 51.48B
+1.21%+7.27%-14.36%-18.96% 50.15B
+0.16%+1.90%+24.83%+11.91% 39.92B
-0.08%+5.10%+43.92%+37.88% 39.24B
-0.35%+7.04%-20.40%+24.54% 32.2B
Average +0.62%+3.73%-0.12%+7.77% 77.22B
Weighted average by Cap. +0.46%+3.41%+2.75%+4.13%

Financials

2026 *2027 *
Net sales 134M 116M 109M 99.47M 188M 12.75B 190M 1.27B 499M 6.37B 502M 491M 21.2B 180M 156M 146M 134M 252M 17.12B 256M 1.71B 671M 8.56B 675M 660M 28.48B
Net income -95.09M -82.52M -77.27M -70.68M -133M -9.06B -135M -904M -355M -4.53B -357M -349M -15.06B -96.42M -83.67M -78.35M -71.67M -135M -9.18B -137M -917M -360M -4.59B -362M -354M -15.27B
Net Debt -137M -119M -112M -102M -193M -13.08B -195M -1.31B -512M -6.54B -516M -504M -21.75B -81.06M -70.35M -65.87M -60.26M -114M -7.72B -115M -771M -302M -3.86B -304M -298M -12.84B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
06/08/26 $14.11 +1.44% 590,198
05/08/26 $13.91 -4.53% 897,075
04/08/26 $14.57 +9.14% 3,341,441
03/08/26 $13.35 +4.05% 2,820,101
31/07/26 $12.83 -10.09% 2,004,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.11USD
Average target price
20.08USD
Spread / Average Target
+42.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock